We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
- Authors
Schneider, Bryan P; Wang, Molin; Radovich, Milan; Sledge, George W; Badve, Sunil; Thor, Ann; Flockhart, David A; Hancock, Bradley; Davidson, Nancy; Gralow, Julie; Dickler, Maura; Perez, Edith A; Cobleigh, Melody; Shenkier, Tamara; Edgerton, Susan; Miller, Kathy D; ECOG 2100
- Abstract
No biomarkers have been identified to predict outcome with the use of an antiangiogenesis agent for cancer. Vascular endothelial growth factor (VEGF) genetic variability has been associated with altered risk of breast cancer and variable promoter activity. Therefore, we evaluated the association of VEGF genotype with efficacy and toxicity in E2100, a phase III study comparing paclitaxel versus paclitaxel plus bevacizumab as initial chemotherapy for metastatic breast cancer.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 28, p4672
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.16.1612